by Paul Krzyzanowski | May 25, 2016
A few weeks ago, I came across an interesting story about a stem cell company with a peculiar patenting strategy. As I looked into it further, I realized I’d stumbled into a complicated corporate plot that became more incredible with every turn. Endonovo Therapeutics...
by Stacey Johnson | Apr 29, 2016
Jennifer Hicks at Forbes has written about a handheld surgical device that can draw stem cells to repair cartilage so that the damaged cartilage can heal itself with its own cells. How cool is that?! The ARC Centre of Excellence for Electromaterials Science in...
by Mark Curtis | Apr 28, 2016
Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and...
by Mark Curtis | Apr 25, 2016
Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma....
by Stacey Johnson | Apr 15, 2016
The picture to the right is of my cat Chloe, all dressed up for her debut on Signals. Amazingly, Franklin West (University of Georgia) thinks domesticated cats (Chloe!) are the ideal vessel for saving big cats of the endangered species kind. The idea is to collect...
by Mark Curtis | Mar 24, 2016
Welcome to your Update from the Clinic for the month of February. bluebird made its debut in the oncology market and treated its first patient with a chimeric antigen receptor (CAR) product targeting a novel antigen. Ziopharm enrolled its first patient in a study...
Comments